Voyager Therapeutics (NASDAQ:VYGR) COO Sells $17,590.65 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 4,569 shares of the stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $3.85, for a total transaction of $17,590.65. Following the completion of the sale, the chief operating officer owned 210,078 shares of the company’s stock, valued at approximately $808,800.30. This trade represents a 2.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Voyager Therapeutics Stock Down 0.9%

Shares of NASDAQ VYGR opened at $3.39 on Friday. The company has a market capitalization of $188.48 million, a PE ratio of -1.57 and a beta of 1.30. The stock’s 50 day moving average price is $3.99 and its 200-day moving average price is $4.08. Voyager Therapeutics, Inc. has a twelve month low of $2.64 and a twelve month high of $5.55.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Privium Fund Management B.V. boosted its position in Voyager Therapeutics by 16.6% during the second quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock worth $79,000 after purchasing an additional 3,596 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Voyager Therapeutics by 9.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 61,775 shares of the company’s stock valued at $249,000 after buying an additional 5,422 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Voyager Therapeutics by 1.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 303,133 shares of the company’s stock worth $1,191,000 after buying an additional 5,560 shares during the period. American Century Companies Inc. grew its stake in Voyager Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock valued at $430,000 after buying an additional 6,748 shares in the last quarter. Finally, Jain Global LLC raised its holdings in Voyager Therapeutics by 44.1% during the 3rd quarter. Jain Global LLC now owns 28,104 shares of the company’s stock valued at $131,000 after acquiring an additional 8,600 shares during the period. 48.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on VYGR shares. Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. HC Wainwright lowered their price objective on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Finally, Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Voyager Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $13.75.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.